Insilico Medicine has dosed the first patient in a Phase III clinical trial for Rentosertib, an AI-discovered drug targeting idiopathic pulmonary fibrosis (IPF). The trial, conducted at multiple centers in China, aims to evaluate the drug's efficacy and safety over 52 weeks in 320 patients. Rentosertib inhibits TNIK, a novel target linked to fibrosis, and showed promising Phase IIa results including improved lung function. Insilico expects the trial to take 3-4 years to complete and aims for regulatory approval to offer a new treatment option for IPF, a serious lung disease with limited therapies. The company also reported strong financial growth in 2026, driven by partnerships and AI-driven drug discovery advancements.
Aduro Clean Technologies announced it will participate in five conferences between October and December 2026, engaging with industry professionals and institutional investors. Key topics include updates on their Hydrochemolytic™ technology for recycl...
Aduro Clean Technologies announced its participation in five major industry and investor conferences from October to December 2026. The company will showcase progress in its Hydrochemolytic™ technology for recycling plastics and upgrading crude oils,...
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Chainlink has formed a strategic partnership with LG CNS, the tech arm of South Korea's LG Group, to develop blockchain infrastructure for the country's $68 billion cryptocurrency market. The collaboration aims to integrate Chainlink's oracle and cro...
Allen Helm, co-founder of Bitcoin for Corporations, discussed key topics including institutional credit and securities linked to Bitcoin, BlackRock's record ETF inflows, and whether financial institutions still view Bitcoin as speculative. The conver...
